Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study
新辅助来曲唑联合帕博西尼治疗HR阳性/HER2阴性早期乳腺癌且Oncotype DX复发评分≥18的患者：DxCARTES研究
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.103733
Guerrero-Zotano, Á; Pérez-García, J M; Ruiz-Borrego, M; Bermejo, B; Gil-Gil, M; de la Haba, J; Alba Conejo, E; Quiroga, V; Carañana, V; Urruticoechea, A; Morales, S; Bellet, M; Antón, A; Fernández-Abad, M; Sánchez-Rovira, P; Calabuig, L; Pérez-Escuredo, J; Sampayo-Cordero, M; Cortés, J; Llombart-Cussac, A
